Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 5/20 | 1.00 |
| ▸ | GSK3B | P49841 | 5/20 | 1.00 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.64 |
| ▸ | MGLL | Q99685 | 2/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA4 | P22748 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | CMA1 | P23946 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.53 |
| ▸ | DAO | P14920 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | PARK7 | Q99497 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3384174 | 0.81 | GSK3A (1.00) | GSK3AGSK3BMGLLCMA1ALDH1A1 | |
| SCHEMBL6941838 | 0.80 | GSK3A (0.67) | GSK3AGSK3BHSP90AA1MGLLCA1 | |
| SCHEMBL19419960 | 0.79 | GSK3A (0.66) | GSK3AGSK3BHSP90AA1MGLLCA1 | |
| SCHEMBL29168851 | 0.78 | RAB9A (0.68) | GSK3AGSK3BALDH1A1 | |
| SCHEMBL30758623 | 0.78 | RAB9A (0.68) | GSK3AGSK3BALDH1A1 | |
| SCHEMBL28967239 | 0.78 | GSK3A (0.64) | GSK3AGSK3BSIGMAR1CA1CA2 | |
| SCHEMBL14678150 | 0.78 | HSP90AA1 (1.00) | GSK3AGSK3BHSP90AA1ALDH1A1KMT2A | |
| SCHEMBL10195154 | 0.78 | GSK3A (0.64) | GSK3AGSK3BSIGMAR1CMA1HRH3 | |
| SCHEMBL20804282 | 0.77 | GSK3A (0.69) | GSK3AGSK3BHSP90AA1MGLLCMA1 | |
| SCHEMBL12615721 | 0.76 | GSK3A (0.60) | GSK3AGSK3BSIGMAR1CMA1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7781463-B2 | Enzyme inhibitors | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2010-08-24 | — | — | US | disclosed |
| US-7666885-B2 | Neurodegenerative disease; anticancer agents; hyperplasia; arterosclerosis; restenosis; non-insulin dependent diabetis; Alzheimer's disease | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2010-02-23 | — | — | US | disclosed |
| US-20080033012-A1 | Enzyme inhibitors | COSENJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS, A SPAIN CORPORATION | 2008-02-07 | — | — | US | disclosed |
| US-6872737-B2 | Heterocyclic inhibitors of glycogen synthase kinase GSK-3 | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2005-03-29 | — | — | US | disclosed |
| US-20050014803-A1 | Enzyme inhibitors | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS, A SPAIN CORPORATION | 2005-01-20 | — | — | US | disclosed |
| US-20030195238-A1 | Drugs such as 4-Benzyl-2-methyl-1,2,4-thiadiazolidine-3,5 -dione inhibitors of glycogen synthase kinase-3 (GSK-3), for prophylaxis of neurodegenerative disorders, cancer, hyperplasia, psoriasis, arteriosclerosis or restinosis | UNIVERSIDAD AUTONOMA DE MADRID (UAM) (ES) | 2003-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080033012-A1 | Enzyme inhibitors | GSK3B, GSK3A, IDE | GSK3A 2/4885GSK3B 1/4885HSP90AA1 3536/4885 |
| US-20030195238-A1 | Drugs such as 4-Benzyl-2-methyl-1,2,4-thiadiazolidine-3,5 -dione inhibitors of glycogen synthase kinase-3 (GSK-3), for prophylaxis of neurodegenerative disorders, cancer, hyperplasia, psoriasis, arteriosclerosis or restinosis | GSK3B, GSK3A, GSKIP | GSK3A 2/4885GSK3B 1/4885HSP90AA1 3493/4885 |
| US-20050014803-A1 | Enzyme inhibitors | GSK3B, GSK3A, IDE | GSK3A 2/4885GSK3B 1/4885HSP90AA1 3536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.